The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

• Main Authors: Raffaele Ornello, Cindy Tiseo, Ilaria Frattale, Giulia Perrotta, Carmine Marini, Francesca Pistoia, Simona Sacco
• Format: Article
• Language: English
• Published: BMC 2019-10-01
• Series: The Journal of Headache and Pain
• Subjects: Migraine; Calcitonin gene-related peptide; Migraine prevention; Monoclonal antibodies; Erenumab
• Online Access: http://link.springer.com/article/10.1186/s10194-019-1054-4

Abstract Background Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patients with prior preventive treatment failures benefit more from the 140 mg dose than the 70 mg. Main body We searched papers indexed in PubMed and conference abstracts published in the last 2 years which assessed the safety and efficacy of erenumab in patients with prior preventive treatment failures. We reviewed the results of 3 randomized controlled trials and their subgroup analyses and open-label extensions. The 140 mg monthly dose of erenumab had a numerical advantage over the 70 mg monthly dose in patients with prior preventive treatment failures, both in EM and CM (with or without medication overuse) during the double blind phases of the trials and their open-label extensions. The numerical difference between the two doses increased with the increase in the number of prior preventive treatment failures. Conclusions The available data suggest that erenumab 140 mg monthly might be preferred over the 70 mg monthly dose in patients with EM or CM and prior preventive treatment failures. Further data are needed to assess the long-term efficacy in clinical practice of the two doses of erenumab, while their safety profile is comparable.